Búsqueda del medicamento por su nombre

Remeron SolTab e Safinamide Mesylate

Definición de la interacción Remeron SolTab e Safinamide Mesylate y posibilidad de tomarlos juntos.

Resultado de la verificación:

Remeron SolTab <> Safinamide Mesylate

Relevancia: 03.11.2023 Examinador: P.M. Shkutko, M.D., in

En la base de datos de directorios oficiales utilizados para crear el servicio, se encontró una interacción confirmada estadísticamente mediante los resultados de la investigación, que puede conducir a consecuencias negativas para la salud del paciente o aumentar el efecto positivo de cada medicamento. Se requiere una consulta médica para resolver el problema de la administración simultanea de los medicamentos.

Consumidor:

El uso de safinamide junto con mirtazapina puede aumentar el riesgo de una rara pero grave enfermedad llamada el síndrome de la serotonina, que puede incluir síntomas tales como confusión, alucinaciones, convulsiones, cambios bruscos en la presión arterial, aumento del ritmo del corazón, fiebre, sudoración excesiva, escalofríos o temblores, visión borrosa, espasmos musculares o rigidez, temblor, incoordinación, estómago calambres, náuseas, vómitos, y diarrea. Su médico puede ser capaz de prescribir alternativas que no interactúan, o usted puede necesitar un control más frecuente de forma segura el uso de ambos medicamentos. Hable con su médico si usted tiene cualquier pregunta o preocupación. Es importante decirle a su médico acerca de todas las medicinas que usted use, incluyendo vitaminas y hierbas. No deje de tomar ningún medicamento sin hablar primero con su médico.

Profesional:

CONTRAINDICADO: Por inhibición del metabolismo de la serotonina, inhibidores de la monoaminooxidasa (Imao), incluyendo safinamide, puede potenciar la actividad farmacológica de los receptores serotoninérgicos agentes, incluyendo los inhibidores de la recaptación de serotonina y noradrenalina (Irsn), la hierba de San Juan, ciclobenzaprina, trazodone, y tricíclicos y tetracíclicos antidepresivos. El resultado puede ser un aumento en el riesgo de síndrome de serotonina, que es una rara pero grave y potencialmente fatal condición se cree que el resultado de la hiperestimulación de tronco cerebral de 5-HT1A y 2A receptores. Clínicamente, la interacción ha sido reportada principalmente en pacientes tratados con inhibidores de la monoamino oxidasa (incluyendo reversible, irreversible, selectivo y no selectivo) y los antidepresivos tricíclicos, especialmente imipramina y clomipramina, que son el más potente de la recaptación de serotonina inhibidores de la clase. Los síntomas del síndrome serotoninérgico pueden incluir cambios en el estado mental, tales como irritabilidad, alteración de la conciencia, confusión, alucinaciones, y coma; la disfunción autonómica tales como taquicardia, hipertermia, diaforesis, temblor, la labilidad de la presión arterial, y midriasis; las anormalidades neuromusculares tales como hiperreflexia, mioclonías, temblor, rigidez, y ataxia; y síntomas gastrointestinales tales como calambres abdominales, náuseas, vómitos, y diarrea.

ADMINISTRACIÓN: la Administración conjunta de safinamide con estos agentes serotoninérgicos se considera contraindicado.

Fuentes

"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA, North Wales, PA.
Levy AB, Bucher P, Votolato N "Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment." Can J Psychiatry 30 (1985): 434-6
Graber MA, Hoehns TB, Perry PJ "Sertraline-phenelzine drug interaction: a serotonin syndrome reaction." Ann Pharmacother 28 (1994): 732-5
"Product Information. Emsam (selegiline)." Bristol-Myers Squibb, Princeton, NJ.
Dardennes RM, Even C, Ballon N, Bange F "Serotonin syndrome caused by a clomipramine-moclobemide interaction." J Clin Psychiatry 59 (1998): 382-3
Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13
Spiker DG, Pugh DD "Combining tricyclic and monoamine oxidase inhibitor antidepressants." Arch Gen Psychiatry 33 (1976): 828-30
Bem JL, Peck R "Dextromethorphan. An overview of safety issues." Drug Saf 7 (1992): 190-9
Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD "Toxic interaction of venlafaxine and isocarboxazide." Lancet 346 (1995): 1298-9
Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6
Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20
Heisler MA, Guidry JR, Arnecke B "Serotonin syndrome induced by administration of venlafaxine and phenelzine." Ann Pharmacother 30 (1996): 84
Phillips SD, Ringo P "Phenelzine and venlafaxine interaction." Am J Psychiatry 152 (1995): 1400-1
"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.
Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2
"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.
Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):
Sovner R, Wolfe J "Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid ." N Engl J Med 319 (1988): 1671
"Product Information. Methylene Blue (methylene blue)." American Regent Laboratories Inc, Shirley, NY.
White K, Pistole T, Boyd JL "Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study." Am J Psychiatry 137 (1980): 1422-5
Sternbach H "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 850-1
Kline SS, Mauro LS, Scala-Bennett DM, Zick D "Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death." Clin Pharm 8 (1989): 510-4
Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8
Feighner JP, Boyer WF, Tyler DL, Neborsky RJ "Adverse consequences of fluoxetine-MAOI combination therapy." J Clin Psychiatry 51 (1990): 222-5
Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62
"Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Rivers N, Horner B "Possible lethal reaction between nardil and dextromethorphan." Can Med Assoc J 103 (1970): 85
Jimenez-Genchi A "Immediate switching from moclobemide to duloxetine may induce serotonin syndrome." J Clin Psychiatry 67 (2006): 1821-1822
Kay DW, Garside RF, Fahy TJ "A double-blind trial of phenelzine and amitriptyline in depressed out- patients. A possible differential effect of the drugs on symptoms." Br J Psychiatry 123 (1973): 63-7
Graham PM, Ilett KF "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 1255-6
Bodner RA, Lynch T, Lewis L, Kahn D "Serotonin syndrome." Neurology 45 (1995): 219-23
Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK "Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports." Neurology 51 (1998): 274-6
"Product Information. Xadago (safinamide)." US WorldMeds LLC, Louisville , KY.
"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.
Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311
"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31
Staufenberg EF, Tantam D "Malignant hyperpyrexia syndrome in combined treatment." Br J Psychiatry 154 (1989): 577-8
"Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.
Feighner JP, Herbstein J, Damlouji N "Combined MAOI, TCA, and direct stimulant therapy of treatment- resistant depression." J Clin Psychiatry 46 (1985): 206-9
Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8
Tackley RM, Tregaskis B "Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction." Anaesthesia 42 (1987): 760-3
"Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.
Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7
Thomas JM, Rubin EH "Case report of a toxic reaction from a combination of tryptophan and phenelzine." Am J Psychiatry 141 (1984): 281-3
Brannan SK, Talley BJ, Bowden CL "Sertraline and isocarboxazid cause a serotonin syndrome." J Clin Psychopharmacol 14 (1994): 144-5
Graham PM, Potter JM, Paterson J "Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction." Lancet 2 (1982): 440
Pope HG Jr, Jonas JM, Hudson JI, Kafka MP "Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan." Am J Psychiatry 142 (1985): 491-2
Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5
Joffe RT, Post RM, Uhde TW "Lack of pharmacokinetic interaction of carbamazepine with tranylcypromine." Arch Gen Psychiatry 42 (1985): 738
Pascual J, Combarros O, Berciano J "Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment." Clin Neuropharmacol 10 (1987): 565-7
Brubacher JR, Hoffman RS, Lurin MJ "Serotonin syndrome from venlafaxine-tranylcypromine interaction." Vet Hum Toxicol 38 (1996): 358-61
Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006): 1466-8
Jacob JE, Wagner ML, Sage JI "Safety of selegiline with cold medications." Ann Pharmacother 37 (2003): 438-41
"Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.
"Product Information. Flexeril (cyclobenzaprine)." Merck & Co, Inc, West Point, PA.
Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36
De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5
Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7
Cetaruk EW, Aaron CK "Hazards of nonprescription medications." Emerg Med Clin North Am 12 (1994): 483-510
Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11
Wright SP "Hazards with monoamine-oxidase inhibitors: a persistent problem." Lancet 1 (1978): 284-5
"Product Information. Manerix (moclobemide)." Hoffmann-La Roche Limited, Mississauga, IA.
Lader M "Combined use of tricyclic antidepressants and monoamine oxidase inhibitors." J Clin Psychiatry 44 (1983): 20-4
Diamond S "The use of sumatriptan in patients on monoamine oxidase inhibitors." Neurology 45 (1995): 1039-40
"Product Information. Eldepryl (selegiline)." Somerset Pharmaceuticals Inc, Tampa, FL.
Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):
Cerner Multum, Inc. "Australian Product Information." O 0
Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763
"Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.
Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2
Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Ketter TA, Post RM, Parekh PI, Worthington K "Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression." J Clin Psychiatry 56 (1995): 471-5
Bhatara VS, Bandettini FC "Possible interaction between sertraline and tranylcypromine." Clin Pharm 12 (1993): 222-5
Yatham LN, Barry S, Mobayed M, Dinan TG "Is the carbamazepine-phenelzine combination safe?." Am J Psychiatry 147 (1990): 367
"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.
Zetin M "Combined use of trimipramine and phenelzine in depression." J Nerv Ment Dis 170 (1982): 246-7
"Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
Waghray SN, Francis K "Epilepsy as an adverse reaction to combined therapy of MAOIs and tricyclics." J R Soc Med 77 (1984): 346
de la Fuente JR, Berlanga C, Leon-Andrade C "Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports." J Clin Psychiatry 47 (1986): 40-1
Suchowersky O, deVries JD "Interaction of fluoxetine and selegiline." Can J Psychiatry 35 (1990): 571-2
"Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
Lefebvre H, Noblet C, Morre N, Wolf LM "Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline." Clin Endocrinol (Oxf) 42 (1995): 95-8
Lydiard RB, White D, Harvey B, Taylor A "Lack of pharmacokinetic interaction between tranylcypromine and carbamazepine." J Clin Psychopharmacol 7 (1987): 360
Weiner LA, Smythe M, Cisek J "Serotonin syndrome secondary to phenelzine-venlafaxine interaction." Pharmacotherapy 18 (1998): 399-403
White K, Simpson G "Combined MAOI-tricyclic antidepressant treatment: a reevaluation." J Clin Psychopharmacol 1 (1981): 264-82
Otte W, Birkenhager TK, van den Broek WW "Fatal interaction between tranylcypromine and imipramine." Eur Psychiatry 18 (2003): 264-5
Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20